EGFR and ovarian carcinoma: However, recent clinical trials targeting EGFR with cetuximab[11-13], matuzumab[14,15], gefitinib[16], and erlotinib[17,18] in epithelial ovarian cancer patients have shown only modest clinical responsiveness.